Autopsy report · NCT00391066
Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)
Cause of deathNo reason given
Life of this trial
- Ran for about 4 years 1 month before it stopped.
- 627 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Biogen
- Sponsor type
- Industry
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- FCR + Lumiliximab; FCR
- Participants
- 627
- Sites
- 194
- Countries
- Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, France, Germany, Greece, India, Israel and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.